FineHeart S.A: FineHeart Breaks New Ground With Successful Removal of the ICOMS FLOWMAKER in a 90-day In-vivo Trial
Easy removal with a beating heart without damage to the myocardium 30 days after implantation
Normal heart functioning 60 days after explantation
Completely sealed operation with dedicated implant fixation system
Quick recovery and short hospital stay
Autonomy and free from complications or infection, or structural damage to the heart and vital organs
FineHeart S.A a preclinical medical device company that has developed the
ICOMS FLOWMAKER, an Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced the successful, simple, and breakthrough implantation and removal of its device in a 90-day in-vivo trial.
IMAGEENS Raises 1.2Mn€ Seed Financing Round to Launch Its First Two Products
LABEL, algorithmic solution for automatic classification and enhancement of medical imaging data
IMAGEENS, a Paris-based medical Artificial Intelligence (AI) startup developing software solutions for the analysis of medical images, has secured 1.2Mn€ in seed financing. The round was led by Anaxago, with a participation from BADGE (Business Angels des Grandes Ecoles), COALESCENCE, and existing IMAGEENS investors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210415005466/en/
IMAGEENS software solutions allow radiologists, cardiologists and vascular surgeons to make personalized decisions and to better assess the cardiovascular risk of their patients, thanks to highly accurate medical imaging data.
Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19 related ARDS
- GARDEN will enroll 60 patients hospitalized for COVID19
- First Patient included at University Hospital of Strasbourg
Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announces the recruitment of the first patient of its phase 2 GARDEN study to treat COVID-19 related acute respiratory distress syndrome (ARDS) with glenzocimab.
GARDEN (clinicaltrials.gov NCT04659109) is a phase 2 study, randomized, double blind, multicenter, placebo controlled, parallel group, exploratory efficacy and safety study of glenzocimab in sars-cov-2-related acute respiratory distress syndrome. GARDEN will enroll 60 patients in France and in Brazil. The Professor Julien POTTECHER, Strasbourg University Hospital, is the Principal Investigator of GARDEN in France. The Professor Victor A. Ham